☰

Matthew J. Maurer, Ph.D. - Publications

Institution:
Johns Hopkins University, Baltimore, MD
Area:
s.cerevisiae, membrane biology, ABC transporters, protein degradation mechanisms
Tree Info Grants Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Maurer MJ, Spear ED, Yu AT, Lee EJ, Shahzad S, Michaelis S. Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast. G3 (Bethesda, Md.). PMID 27172186 DOI: 10.1534/G3.116.027953  0.543
2011 Thompson CA, Maurer MJ, Allmer C, Slager SL, Yost KJ, Macon WR, Ansell SM, Inwards DJ, Habermann TM, Link BK, Cerhan JR. Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8059. PMID 28023542 DOI: 10.1200/Jco.2011.29.15_Suppl.8059  0.321
2009 Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE. Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8508. PMID 27960859 DOI: 10.1200/Jco.2009.27.15_Suppl.8508  0.347
2008 Metzger MB, Maurer MJ, Dancy BM, Michaelis S. Degradation of a cytosolic protein requires endoplasmic reticulum-associated degradation machinery. The Journal of Biological Chemistry. 283: 32302-16. PMID 18812321 DOI: 10.1074/Jbc.M806424200  0.603
2008 Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore DF, Kurtin P, Witzig TE. A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Journal of Clinical Oncology. 26: 8500-8500. DOI: 10.1200/Jco.2008.26.15_Suppl.8500  0.361
2007 Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF, Zwiebel JA, Buckner JC. N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. 25: 2004-2004. DOI: 10.1200/Jco.2007.25.18_Suppl.2004  0.32
2005 Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5294-304. PMID 15998902 DOI: 10.1200/Jco.2005.23.622  0.344
2005 Galanis E, Buckner JC, Maurer MJ, Hidalgo M, Kreisberg JI, Peralba J, Jenkins RB, Walsh DJ. N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis Journal of Clinical Oncology. 23: 1505-1505. DOI: 10.1200/Jco.2005.23.16_Suppl.1505  0.313
2004 Micallef IN, Kahl BS, Gayko U, Cesano A, Ansell SM, Geyer S, Inwards DJ, Maurer MJ, Horning S, Habermann TM. Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) Journal of Clinical Oncology. 22: 6580-6580. DOI: 10.1200/Jco.2004.22.90140.6580  0.346
Show low-probability matches.